SG11201501907YA - Method of synthesizing thyroid hormone analogs and polymorphs thereof - Google Patents
Method of synthesizing thyroid hormone analogs and polymorphs thereofInfo
- Publication number
- SG11201501907YA SG11201501907YA SG11201501907YA SG11201501907YA SG11201501907YA SG 11201501907Y A SG11201501907Y A SG 11201501907YA SG 11201501907Y A SG11201501907Y A SG 11201501907YA SG 11201501907Y A SG11201501907Y A SG 11201501907YA SG 11201501907Y A SG11201501907Y A SG 11201501907YA
- Authority
- SG
- Singapore
- Prior art keywords
- polymorphs
- thyroid hormone
- hormone analogs
- synthesizing
- synthesizing thyroid
- Prior art date
Links
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title 1
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702137P | 2012-09-17 | 2012-09-17 | |
| US201361790432P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/060177 WO2014043706A1 (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501907YA true SG11201501907YA (en) | 2015-04-29 |
Family
ID=50278769
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501907YA SG11201501907YA (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| SG10202006058QA SG10202006058QA (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| SG10201705984XA SG10201705984XA (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202006058QA SG10202006058QA (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| SG10201705984XA SG10201705984XA (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9266861B2 (en) |
| EP (4) | EP4406594A3 (en) |
| JP (7) | JP6616688B2 (en) |
| KR (4) | KR102138750B1 (en) |
| CN (2) | CN105008335B (en) |
| AR (1) | AR092872A1 (en) |
| AU (1) | AU2013315017C1 (en) |
| BR (2) | BR122021024202B1 (en) |
| CA (3) | CA3090070C (en) |
| DK (2) | DK3689853T3 (en) |
| ES (2) | ES2795450T3 (en) |
| HK (1) | HK1212682A1 (en) |
| IL (6) | IL314360A (en) |
| IN (1) | IN2015DN03133A (en) |
| MX (2) | MX364661B (en) |
| MY (1) | MY170520A (en) |
| NZ (2) | NZ739645A (en) |
| RU (2) | RU2668960C2 (en) |
| SG (3) | SG11201501907YA (en) |
| TW (4) | TWI681957B (en) |
| WO (1) | WO2014043706A1 (en) |
| ZA (1) | ZA201501795B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201501907YA (en) | 2012-09-17 | 2015-04-29 | Madrigal Pharmaceuticals Inc | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| EP3528817B1 (en) | 2016-10-18 | 2022-05-25 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| EP3725779A4 (en) * | 2018-01-23 | 2021-02-24 | Shenzhen TargetRx, Inc. | Substituted pyridazinone compound |
| EP3807267A4 (en) | 2018-06-12 | 2022-03-16 | Sichuan Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
| WO2019242766A1 (en) * | 2018-06-22 | 2019-12-26 | 成都海创药业有限公司 | Deuterated mgl-3196 compound and use thereof |
| TW202019914A (en) * | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
| AU2019359141A1 (en) * | 2018-10-12 | 2021-04-22 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| JP7445996B2 (en) * | 2019-02-21 | 2024-03-08 | ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド | Novel compounds and their use as thyroid hormone receptor agonists |
| MA55890A (en) | 2019-05-08 | 2022-03-16 | Aligos Therapeutics Inc | THR-BETA MODULATORS AND METHODS OF USE THEREOF |
| CN111909137B (en) * | 2019-05-10 | 2023-05-30 | 深圳微芯生物科技股份有限公司 | Pyridazinone derivative and application thereof |
| CN114174282A (en) * | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | Pyridazinone derivatives as thyroxine receptor-beta agonists and uses thereof |
| CN112442013B (en) * | 2019-09-04 | 2022-07-26 | 广东东阳光药业有限公司 | Compound serving as thyroid hormone beta receptor agonist and application thereof |
| WO2021063367A1 (en) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | Resmetirom crystal form and preparation method therefor and use thereof |
| CN112707892A (en) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof |
| US20230089582A1 (en) | 2019-11-26 | 2023-03-23 | Kpc Pharmaceuticals, Inc | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| WO2021121210A1 (en) * | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | Fused-ring derivative, and preparation method therefor and medical use thereof |
| WO2021129465A1 (en) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | Resmetirom crystal, preparation method for same, and uses thereof |
| WO2022041026A1 (en) * | 2020-08-27 | 2022-03-03 | InventisBio Co., Ltd. | Pyridazinone compounds |
| JP2023541870A (en) * | 2020-09-10 | 2023-10-04 | ▲蘇▼州科睿思制▲葯▼有限公司 | Crystal form of RESMETIROM, its preparation method, and its use |
| US20230364099A1 (en) | 2020-10-19 | 2023-11-16 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| US20240307405A1 (en) | 2021-02-01 | 2024-09-19 | Madrigal Pharmaceuticals, Inc. | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
| CN114907327A (en) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Crystal form of Resmetirom and preparation method and application thereof |
| CN115073429A (en) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | Salt form and crystal form of 1,2, 4-triazine-3, 5-diketone compound and preparation method thereof |
| AU2022348966A1 (en) | 2021-09-27 | 2024-04-11 | Madrigal Pharmaceuticals, Inc. | Resmetirom for reducing liver volume |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) * | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| ATE435870T1 (en) * | 2003-01-28 | 2009-07-15 | Academisch Ziekenhuis Leiden | PEPTIDE INHIBITORS OF TOXINS DERIVED FROM LL-37 |
| CN100469769C (en) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| ITRM20030363A1 (en) | 2003-07-24 | 2005-01-25 | Fernando Goglia | COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM. |
| US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| US20060229267A1 (en) * | 2004-06-01 | 2006-10-12 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| BRPI0517947A (en) | 2004-11-02 | 2008-10-21 | Univ Northwestern | pyridazine compound, compositions and methods |
| RU2379295C2 (en) | 2005-07-21 | 2010-01-20 | Ф.Хоффманн-Ля Рош Аг | Pyridasinone derivatives as agonists of thyroid hormone receptor |
| NZ582273A (en) | 2007-06-06 | 2011-06-30 | Torrent Pharmaceuticals Ltd | Thyroid like compounds |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| SG11201501907YA (en) * | 2012-09-17 | 2015-04-29 | Madrigal Pharmaceuticals Inc | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| JP6553067B2 (en) | 2014-02-14 | 2019-07-31 | センプラ ファーマシューティカルズ，インコーポレイテッド | Compositions and methods for treating diabetes and liver disease |
| EP3528817B1 (en) | 2016-10-18 | 2022-05-25 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| EP3807267A4 (en) | 2018-06-12 | 2022-03-16 | Sichuan Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
| TW202019914A (en) | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
| AU2019359141A1 (en) | 2018-10-12 | 2021-04-22 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
-
2013
- 2013-09-17 SG SG11201501907YA patent/SG11201501907YA/en unknown
- 2013-09-17 AR ARP130103332A patent/AR092872A1/en active IP Right Grant
- 2013-09-17 DK DK20157696.4T patent/DK3689853T3/en active
- 2013-09-17 IN IN3133DEN2015 patent/IN2015DN03133A/en unknown
- 2013-09-17 EP EP24173563.8A patent/EP4406594A3/en active Pending
- 2013-09-17 BR BR122021024202-0A patent/BR122021024202B1/en active IP Right Grant
- 2013-09-17 KR KR1020187034908A patent/KR102138750B1/en active IP Right Grant
- 2013-09-17 CA CA3090070A patent/CA3090070C/en active Active
- 2013-09-17 ES ES13837402T patent/ES2795450T3/en active Active
- 2013-09-17 WO PCT/US2013/060177 patent/WO2014043706A1/en active Application Filing
- 2013-09-17 CA CA2884481A patent/CA2884481C/en active Active
- 2013-09-17 SG SG10202006058QA patent/SG10202006058QA/en unknown
- 2013-09-17 BR BR112015005891A patent/BR112015005891A2/en not_active Application Discontinuation
- 2013-09-17 TW TW107137798A patent/TWI681957B/en active
- 2013-09-17 ES ES20157696T patent/ES2907926T3/en active Active
- 2013-09-17 RU RU2015114327A patent/RU2668960C2/en active
- 2013-09-17 CN CN201380059943.5A patent/CN105008335B/en active Active
- 2013-09-17 KR KR1020217019940A patent/KR102363776B1/en active IP Right Grant
- 2013-09-17 NZ NZ73964513A patent/NZ739645A/en unknown
- 2013-09-17 EP EP13837402.0A patent/EP2895466B1/en active Active
- 2013-09-17 IL IL314360A patent/IL314360A/en unknown
- 2013-09-17 CN CN201810077707.0A patent/CN108101851A/en active Pending
- 2013-09-17 EP EP20157696.4A patent/EP3689853B1/en active Active
- 2013-09-17 TW TW110117935A patent/TWI804870B/en active
- 2013-09-17 MY MYPI2015000591A patent/MY170520A/en unknown
- 2013-09-17 NZ NZ705827A patent/NZ705827A/en unknown
- 2013-09-17 KR KR1020157009807A patent/KR101966490B1/en active IP Right Grant
- 2013-09-17 MX MX2015003418A patent/MX364661B/en active IP Right Grant
- 2013-09-17 TW TW102133687A patent/TWI652260B/en active
- 2013-09-17 TW TW108132827A patent/TWI755628B/en active
- 2013-09-17 IL IL288133A patent/IL288133B1/en unknown
- 2013-09-17 CA CA3111317A patent/CA3111317C/en active Active
- 2013-09-17 SG SG10201705984XA patent/SG10201705984XA/en unknown
- 2013-09-17 AU AU2013315017A patent/AU2013315017C1/en active Active
- 2013-09-17 KR KR1020207005528A patent/KR20200023528A/en not_active IP Right Cessation
- 2013-09-17 JP JP2015532148A patent/JP6616688B2/en active Active
- 2013-09-17 RU RU2018128393A patent/RU2018128393A/en unknown
- 2013-09-17 DK DK13837402.0T patent/DK2895466T3/en active
- 2013-09-17 EP EP21209827.1A patent/EP4023641B1/en active Active
-
2015
- 2015-03-09 IL IL237628A patent/IL237628B/en active IP Right Grant
- 2015-03-16 ZA ZA2015/01795A patent/ZA201501795B/en unknown
- 2015-03-17 MX MX2018014924A patent/MX2018014924A/en unknown
- 2015-03-17 US US14/660,720 patent/US9266861B2/en active Active
-
2016
- 2016-01-18 HK HK16100496.1A patent/HK1212682A1/en unknown
- 2016-02-17 US US15/046,213 patent/US9968612B2/en active Active
-
2017
- 2017-12-26 JP JP2017249107A patent/JP6532931B2/en active Active
-
2018
- 2018-04-10 US US15/949,389 patent/US10376517B2/en active Active
- 2018-05-27 IL IL259610A patent/IL259610B/en active IP Right Grant
- 2018-11-20 JP JP2018217045A patent/JP6765408B2/en active Active
-
2019
- 2019-02-25 IL IL265030A patent/IL265030B/en active IP Right Grant
- 2019-07-01 US US16/458,546 patent/US10894050B2/en active Active
- 2019-08-27 JP JP2019154299A patent/JP6899413B2/en active Active
-
2020
- 2020-02-10 JP JP2020020343A patent/JP7038745B2/en active Active
- 2020-06-15 IL IL275393A patent/IL275393B/en unknown
- 2020-12-11 US US17/118,706 patent/US11564926B2/en active Active
-
2022
- 2022-03-07 JP JP2022034154A patent/JP7436542B2/en active Active
- 2022-12-15 US US18/066,677 patent/US20230210856A1/en active Pending
-
2023
- 2023-12-22 US US18/393,813 patent/US11986481B2/en active Active
- 2023-12-22 US US18/393,818 patent/US20240148742A1/en not_active Abandoned
-
2024
- 2024-02-07 JP JP2024016915A patent/JP2024056793A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288133A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| AP3965A (en) | Anthelminitic compounds and compositions and method of using thereof | |
| EP2826205A4 (en) | Method of navigating through digital content | |
| EP2800476A4 (en) | Method of feeding | |
| GB201207208D0 (en) | Compound and method of manufacture | |
| EP2914293A4 (en) | Methods of using fviii polypeptide | |
| HK1214240A1 (en) | Method for preparation of imidodisulfuryl compounds | |
| HK1201532A1 (en) | Method for preparation of medetomidine | |
| EP2800747A4 (en) | Polymorphs of perampanel | |
| EP2902015A4 (en) | Preparation method of agomelatine solid preparation | |
| IL238515A0 (en) | Method of preparation of a-galactosyl ceramides compounds | |
| GB201215942D0 (en) | Method of treatent | |
| HK1216419A1 (en) | Method of synthesis | |
| EP2928469A4 (en) | Polymorph forms of desazadesferrithiocin analogs | |
| IL233446A0 (en) | Polymorphs of perampanel | |
| GB201211170D0 (en) | Method of feeding | |
| GB201211167D0 (en) | method of feeding | |
| GB201211168D0 (en) | Method of feeding | |
| GB201211169D0 (en) | Method of feeding | |
| GB201211166D0 (en) | Method of feeding | |
| GB201203868D0 (en) | Method of feeding | |
| GB201200132D0 (en) | Method of feeding | |
| SG10201610527UA (en) | Mixotrophic method of aquaculture | |
| SG10201701021XA (en) | Method of synthesis | |
| TWM432415U (en) | Improved structure of walk aid apparatus |